pindolol has been researched along with guanabenz in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caron, G; Ermondi, G | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Agranat, I; Atlas, D; Cohen, S; Diamant, S; Goldblum, A | 1 |
| Morgan, TO | 1 |
| Lowenthal, DT | 1 |
8 other study(ies) available for pindolol and guanabenz
| Article | Year |
|---|---|
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Beta-adrenergic activity and conformation of the antihypertensive specific alpha 2-agonist drug, guanabenz.
Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Animals; Binding, Competitive; Clonidine; Cyclic AMP; Erythrocytes; Guanabenz; Guanidines; In Vitro Techniques; Iodocyanopindolol; Models, Molecular; Molecular Conformation; Pindolol; Quantum Theory; Receptors, Adrenergic, beta; Turkeys; X-Ray Diffraction | 1985 |
Comparison of a centrally acting antihypertensive agent and beta-adrenergic blocking agents for the treatment of hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Female; Guanabenz; Humans; Hypertension; Male; Middle Aged; Pindolol; Potassium; Propranolol; Pulse; Time Factors | 1984 |
New drugs for hypertension.
Topics: Antihypertensive Agents; Bumetanide; Diltiazem; Dipeptides; Enalapril; Guanabenz; Guanidines; Humans; Indapamide; Labetalol; Nifedipine; Pindolol; Verapamil | 1984 |